- Cited — Davis v Lloyds Bank Plc (Rev 1) 2021-04-16
“…[2004] UKHL 46, [2005] RPC 9 at [64]:…”
- Cited — Anan Kasei Co Ltd & Anor v Neo Chemicals And Oxides Ltd & Anor 2019-10-09
“…ure of the claim in that case. Far from being a straightforward product claim (as in this case) or even a product-by-process claim (as discussed in Kirin-Amgen [2005] RPC 9, paras 86-91 and 101), the claim was to a product identified in part by how it was made and in part by what it did…”
- Cited — Anan Kasei Co Ltd & Anor v Neo Chemicals And Oxides Ltd & Anor 2019-10-09
“…ther someone has crossed the boundary “yes” or “no”. That, I think, is what Lord Hoffmann meant in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9 at [126] by a “fuzzy boundary” (a phrase which is now part of the jargon of patent lawyers). The boundary may be fuzzy, but it is still a boundary.…”
- Cited — Icescape Ltd v Ice-World International BV & Ors 2018-10-10
“…The law was reviewed by the House of Lords in Kirin-Amgen v Hoechst Marion Roussel [2005] RPC 9. This decision was given before the Protocol to art.69 was amended by EPC 2000 to introduce art.2, but the terms of the amendment were settled and were before …”
- Cited — Regeneron Pharmaceuticals, Inc v Kymab Ltd & Anor 2018-03-28
“…ent the subject of the Board’s own earlier decision T 412/93 and the decision of the House of Lords in Kirin-Amgen Inc v Hoechst Marion Roussel [2004] UKHL 46, [2005] RPC 9, to which we will come. For present purposes, we need refer only to the discussion by the Board of the balance to be drawn between the need for fair protection…”
- Cited — Regeneron Pharmaceuticals, Inc v Kymab Ltd & Anor 2018-03-28
“…Lord Hoffmann provided further guidance in Kirin-Amgen Inc v Hoechst Marion Roussel [2004] UKHL 46, [2005] RPC 9. A team from Amgen was the first to clone and sequence the gene for erythropoetin (“EPO”). Once that sequence had been discovered it was possible to make the p…”